Biohaven reports progress in Graves' disease program, Phase 3 trial of BHV-1300 enrolling at 55+ sites

Biohaven announced progress across its Graves' disease program, including active enrollment in the pivotal Phase 3 trial of BHV-1300 at 55+ active sites in the U.S. and Canada, with more opening in the UK, Japan, Australia and EU, and three scientific presentations at the American Thyroid Association meeting.

Detected & updated continuously · Source: Nebula